NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the peer-reviewed publication of clinical experience with its OneRF sEEG-Guided Radiofrequency Ablation System in the journal Stereotactic and Functional Neurosurgery. The article, accessible via PubMed at https://pubmed.ncbi.nlm.nih.gov/41785222/, describes the first clinical use of the only FDA-cleared system capable of nervous tissue ablation using the same sEEG electrode for both diagnostic and therapeutic applications.
The case series reports on four consecutive patients with drug-resistant epilepsy treated at a leading U.S. epilepsy center. The authors found the procedure safe and easy to integrate into existing stereotactic neurosurgical workflows, allowing treatment either in the operating room or at the patient's bedside. The technology enabled RF ablation without removing or repositioning already implanted sEEG electrodes, with real-time temperature monitoring for precise, controlled lesions. No adverse events occurred, and all four patients experienced reductions in seizure burden. The procedure also provided information guiding subsequent surgical decisions.
The OneRF Ablation System is NeuroOne's first device with a therapeutic indication and the company's third FDA 510(k)-cleared device. NeuroOne estimates the combined sEEG and brain ablation market at $200 million worldwide and growing. The company markets a platform with four FDA-cleared product families, including Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System, and OneRF Trigeminal Nerve Ablation System. For more information, visit nmtc1.com.
